Please login to the form below

Not currently logged in

Exelixis bounces back with new prostate cancer data

Announces encouraging results after initial trial fail

Exelixis logo

Exelixis has announced that its lead drug cabozantinib, in combination with Roche’s Tecentriq, demonstrated encouraging results in a phase 1 prostate cancer trial.

The COSMIC-021 trial evaluated the combination treatment in patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), whose disease had progressed on prior novel hormone therapy.

Exelixis previously attempted to tackle prostate cancer with cabozantinib back in 2014, but the drug was unable to show any survival benefit on its own. Following the disappointing results, Exelixis was forced to slash its workforce by 70%, in order to buy time to bring its other pipeline projects to fruition.

It seems like that sacrifice was worth it, with cabozantinib in combination with PD-1 inhibitor Tecentriq (atezolizumab) hitting the primary endpoint of an improved objective response rate. The ORR was 32% –  that includes two complete responses and 12 partial responses.

Importantly, among the 36 patients with high-risk clinical features – including visceral metastases and/or extra-pelvic lymph node metastases – the ORR was 33%.

"Emerging data suggests a tolerable safety profile and encouraging efficacy for this combination that may hold promise for these patients with limited treatment options, potentially providing patients with more time before the need for treatment with chemotherapy. We look forward to additional results as the trial progresses," said Neeraj Agarwal, professor at Huntsman Cancer Center, University of Utah and an investigator of the trial.

Cabozantinib, a c-MET and VEGFR2 inhibitor, is already approved under the brand name Cometriq as a treatment for progressive, metastatic medullary thyroid cancer in the US and Europe.

It is also approved for use under the name Cabometyx in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) – net product revenues from the entire franchise are expected to be between $725m and $775 this year, according to Exelixis’ recently reported financial guidance for 2020.

Exelixis is also testing cabozantinib in a host of other clinical trials, including a phase 3 trial in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) in previously untreated advanced or metastatic RCC.

It is also testing cabozantinib in combination with Tecentriq in another setting – previously untreated HCC. Analysis from a phase 3 trial of this combination are due as early as the second half of 2020.

Exelixis intends to file the cabozantinib/Tecentriq combination with the FDA for accelerated approval in metastatic CRPC by 2021.

Article by
Lucy Parsons

11th February 2020

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...
Spotlight interview: 15 minutes on Independent Medical Education
Celeste Kolanko, Managing Director of Liberum, OPEN Health takes 15 minutes to answer some key questions on independent medical education....